Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

LSEG reports first-quarter rise in total income

(Sharecast News) - London Stock Exchange Group reported an 8.7% increase in total income excluding recoveries in the first quarter on Thursday, or 7.8% on an organic basis, supported by solid growth across all business divisions and elevated market activity. The FTSE 100 exchange operator reiterated its full-year guidance, citing confidence in continued growth and margin improvement.

It said data and analytics revenue rose 5.1%, with gains led by analytics, and data and feeds.

Within that segment, analytics grew 7.4% on strong demand for fixed income tools and new Microsoft-partnered API capabilities, while data and feeds advanced 6.6% on innovation in real-time services and pricing products.

The workflows business delivered 3.4% growth, bolstered by enhancements across product lines.

LSEG said it was on track to sunset its Eikon platform by mid-2025.

FTSE Russell meanwhile grew 9.6%, driven by steady demand for equity benchmarks and higher asset-based revenues supported by inflows and improved market levels.

Risk Intelligence also posted strong results, up 10.7%, reflecting robust demand for World-Check and digital identity offerings.

Markets income climbed 10.7%, or 13.5% including the ICD acquisition, as heightened geopolitical and economic uncertainty lifted trading volumes.

Tradeweb recorded another record quarter with $2.55trn in average daily volume, contributing to a 17.3% organic rise in the fixed income, derivatives and other categories.

Foreign exchange revenue increased 12.3%, while OTC derivatives rose 16.8%.

Equities advanced 3.1%, though primary issuance remained subdued.

Securities and reporting fell 9.8% due to the prior-year loss of Euronext clearing business, and net treasury income declined 6.3% for the same reason.

Group cost of sales rose 7.2%, slightly below revenue growth, while gross profit increased 7.5%.

Annual subscription value growth reached 6.4% on strong sales and high retention.

By the end of April, LSEG said it had completed £245m of its planned £500m share buyback.

It also repurchased $250m of its 2031 dollar bonds in March to take advantage of current interest rates.

LSEG reaffirmed its guidance for 2025, including 6.5% to 7.5% organic income growth excluding recoveries, a 50 to 100 basis point improvement in EBITDA margin, and equity free cash flow of at least £2.4bn.

"We have started the year strongly, delivering another quarter of good growth," said chief executive officer David Schwimmer.

"Our data and analytics business accelerated further, and risk intelligence and FTSE Russell continued to perform well.

"Our markets division saw strong broad-based growth against a backdrop of elevated volatility, which has persisted into April reflecting continuing uncertainty around the outlook for financial markets and the global economy more broadly."

Schwimmer said the company was continuing to drive the strategic transformation of its business - building a strong product pipeline, investing in our engineering talent and delivering on the Microsoft partnership.

"Our strong first quarter performance is testament to the value of our diversified business model.

"We look forward to further progress in the rest of the year, consistent with our financial targets."

At 0931 BST, shares in London Stock Exchange Group were down 0.04% at 11,620p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.